GSK Tykerb Poised To Make Inroads Against Roche's Herceptin After Adding First-Line Indication

GlaxoSmithKline's orally available cancer drug Tykerb (lapatinib) is poised to make inroads against Roche's Herceptin (trastuzumab) in the fight against one of the more deadly manifestations of metastatic breast cancer in post-menopausal women